The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

Proteasome inhibitor resistance is a challenge for myeloma therapy. Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome. Bortezomib-resistant myeloma cells down-regulate the activation status of the unfolded protein response, and up-regulate β2 proteasome activity. T...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Haematologica
Hlavní autoři: Kraus, Marianne, Bader, Juergen, Geurink, Paul P., Weyburne, Emily S., Mirabella, Anne C., Silzle, Tobias, Shabaneh, Tamer B., van der Linden, Wouter A., de Bruin, Gerjan, Haile, Sarah R., van Rooden, Eva, Appenzeller, Christina, Li, Nan, Kisselev, Alexei F., Overkleeft, Herman, Driessen, Christoph
Médium: Artigo
Jazyk:Inglês
Vydáno: Ferrata Storti Foundation 2015
Témata:
Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4591768/
https://ncbi.nlm.nih.gov/pubmed/26069288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2014.109421
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky